All In Biotech

Drug Trial Radar · NCT02273375

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,415 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,415

Actual

Start

Feb 24, 2015

Primary completion

Jul 23, 2025

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Intergroupe Francophone de Cancerologie Thoracique; Thoracic Oncology Group of Australasia (TOGA); National Health and Medical Research Council, Australia; National Cancer Institute, Naples; Central and Eastern European Oncology Group; Dutch Society of Physicians for Pulmonology and Tuberculosis; Korean Cancer Study Group; Fundación GECP; West Japan Oncology Group; Chinese Thoracic Oncology Group
First posted
Oct 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • MEDI4736Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene RearrangementsTime frame: Up to 8.3 years

Locations

271 sites in 19 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • USC Norris/Comprehensive Cancer Centre

    Los Angeles, California

  • National Jewish Health

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Duke University Medical Center

    Durham, North Carolina

  • Hematology and Oncology Associates of NEPA

    Dunmore, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • The Reading Hospital Medical Center

    West Reading, Pennsylvania

  • Flinders Medical Center

    Adelaide, Australia

  • Canberra Hospital

    Garran, Australia

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Coffs Habour Health Campus - NCCI

    Coffs Harbour, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • St. George Hospital, Cancer Care Centre

    Kogarah, New South Wales, Australia

  • Liverpool Cancer Therapy Centre, Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Northern Cancer Institute St Leonards

    St Leonards, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Mater Medical Centre

    Brisbane, South, QLD, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Frankston Hospital - Peninsula Oncology Centre

    Frankston, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Royal Melbourne Hospital Research Foundation

    Parkville, Victoria, Australia

  • Epworth HealthCare - Richmond

    Richmond, Victoria, Australia

  • Border Medical Oncology

    Wodonga, Victoria, Australia

  • St. Vincent's Hospital

    Victoria Park, Victoria Park, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Sir Charles Gairdner Hospital

    Perth, Western Australia, Australia

  • St John of God Subiaco

    Subiaco, Western Australia, Australia

  • Suporte Nutricional e Quimioterapia LTDA PRONUTRIR

    Fortaleza, Ceará, Brazil

  • Hospital Evangelico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Espírito Santo, Brazil

  • Cetus Hospital Dia Oncologia

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto Nacional de Cancer (INCA)

    Rio de Janeiro, Rio de Janeiro, Brazil

Showing 40 of 271 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.